Healthcare is a hot investment area in the Asia-Pacific region. In the wake of the new crown outbreak, the region has been exposed to a significant lack of medical infrastructure. Moreover, with the gradual aging of the population structure in the Asia-Pacific region, the demand for medical services is increasing, which will make the governments of countries that are already stretched in terms of budget face a heavier financial burden, and highlight the importance of private capital. Although the Asia-Pacific region still faces a series of challenges in life sciences and healthcare investment, a series of positive factors such as macroeconomic, demographic and digital trends are enough to keep investors interested.

Financial Asia magazine (FinanceAsia) and DFIN jointly published 《Life Sciences and Healthcare Industry Report 2023The aim is to provide readers with investment references and insights in the field through a refined and comprehensive overview. The study's findings:

• Despite the challenges of 2022Life Sciences and Healthcare Industry Expected to Recover in 2023. The industry is expected to see strong growth as governments and businesses continue to focus on the health and well-being of people in response to the growing consumer demand for personalized care. Most respondents are optimistic about the industry's growth prospects and investor attention.
• An overwhelming 80% of investors expect to participate in life sciences and healthcare transactions (financings, mergers and acquisitions, public listings) in the next two years.. In contrast, only 40 per cent of respondents have participated in transactions in this area in the past two years. Among investors who are not currently involved in this field, 100 percent of the respondents said they are ready to invest when the right opportunity arises.
• An aging population and increasing pressure on the public health care system will generate more demand, which willAsia-Pacific attracts more attention from investors. The rise of health consumerism and digital innovation will become the dominant factors in the application and supply of products and services in the life sciences and healthcare sectors.
• Investors expect both M & A activity and foreign investment to grow, especially in mature markets and resource-rich regions. The majority of investors (56.3 percent) expect both the number and value of M & A deals to grow over the next two years.
• Factors such as lengthy and complex due diligence, data and intellectual property protection, increasing regulatory requirements, and resource-intensive R & D processes will all pose challenges. While dealmaking is on track for a recovery in 2023,Under the background of continuous industry-wide integration, investment bidding for a small number of enterprises in the late stage of research and development will face fierce competition..
• Medical technology and devices (25.0 percent), biotechnology (19.4 percent), pharmaceutical R & D (19.4 percent) and healthcare solutions (19.4 percent) areThe most active vertical areasand is expected to attract significant investment and mergers and acquisitions.